Pantheon Bioscience
Platform of Bacterial Defense Mechanism
Company Overview
Snapshot
Founded in December 2017 by Prof. Rotem Sorek, Pantheon Bioscience operates with 1–10 employees. The company secured funding across two rounds from two investors. In December 2017, Pantheon Bioscience developed molecular tools based on new anti-phage defense systems.
Business overview
Pantheon Bioscience develops molecular tools leveraging novel anti-phage defense systems identified by Professor Rotem Sorek's lab at the Weizmann Institute of Science. The company focuses on understanding the mechanisms of action of these systems to create biotechnological applications. Pantheon Bioscience operates within the Health Tech & Life Sciences sector, specifically targeting the Pharma & Medical Biotechnology and Drugs Discovery & Development industries.
Log in to access full profile ›Company Intelligence Q&A
- What is Pantheon Bioscience's primary focus?
- Pantheon Bioscience focuses on developing molecular tools based on new anti-phage defense systems discovered by Professor Rotem Sorek's lab at the Weizmann Institute of Science.
- When was Pantheon Bioscience founded?
- Pantheon Bioscience was founded in December 2017.
- Who is a co-founder of Pantheon Bioscience?
- Prof. Rotem Sorek is a co-founder of Pantheon Bioscience.
- What significant technology development occurred in December 2017?
- In December 2017, Pantheon Bioscience developed molecular tools based on new anti-phage defense systems.
- What is the operational status of Pantheon Bioscience?
- Pantheon Bioscience is currently non-active and ceased to operate in September 2021.